Your browser doesn't support javascript.
loading
Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux.
Ganz, Robert A; Edmundowicz, Steven A; Taiganides, Paul A; Lipham, John C; Smith, C Daniel; DeVault, Kenneth R; Horgan, Santiago; Jacobsen, Garth; Luketich, James D; Smith, Christopher C; Schlack-Haerer, Steven C; Kothari, Shanu N; Dunst, Christy M; Watson, Thomas J; Peters, Jeffrey; Oelschlager, Brant K; Perry, Kyle A; Melvin, Scott; Bemelman, Willem A; Smout, André J P M; Dunn, Dan.
Affiliation
  • Ganz RA; Minnesota Gastroenterology PA, Plymouth, Minnesota. Electronic address: rganz@mngastro.com.
  • Edmundowicz SA; Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri.
  • Taiganides PA; Knox Regional Heartburn Treatment Center, Mount Vernon, Ohio.
  • Lipham JC; Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Smith CD; Department of Surgery, Mayo Clinic, Jacksonville, Florida.
  • DeVault KR; Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.
  • Horgan S; Department of Surgery, University of California at San Diego, San Diego, California.
  • Jacobsen G; Department of Surgery, University of California at San Diego, San Diego, California.
  • Luketich JD; Division of Thoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Smith CC; Southern Reflux Center at Albany Surgical Center, Albany, Georgia.
  • Schlack-Haerer SC; Department of Gastroenterology, Gundersen Health System, LaCrosse, Wisconsin.
  • Kothari SN; Department of Surgery, Gundersen Health System, LaCrosse, Wisconsin.
  • Dunst CM; Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic, Portland, Oregon.
  • Watson TJ; Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York.
  • Peters J; University Hospitals, Cleveland, Ohio.
  • Oelschlager BK; Department of Surgery, University of Washington, Seattle, Washington.
  • Perry KA; Department of Surgery, The Ohio State University, Columbus, Ohio.
  • Melvin S; Department of Surgery, The Ohio State University, Columbus, Ohio.
  • Bemelman WA; Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Smout AJ; Division of Gastroenterology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Dunn D; Division of Surgery, Abbott-Northwestern Hospital, Minneapolis, Minnesota.
Clin Gastroenterol Hepatol ; 14(5): 671-7, 2016 May.
Article in En | MEDLINE | ID: mdl-26044316
ABSTRACT
BACKGROUND &

AIMS:

Based on results from year 2 of a 5-year trial, in 2012 the US Food and Drug Administration approved the use of a magnetic device to augment lower esophageal sphincter function in patients with gastroesophageal reflux disease (GERD). We report the final results of 5 years of follow-up evaluation of patients who received this device.

METHODS:

We performed a prospective study of the safety and efficacy of a magnetic device in 100 adults with GERD for 6 months or more, who were partially responsive to daily proton pump inhibitors (PPIs) and had evidence of pathologic esophageal acid exposure, at 14 centers in the United States and The Netherlands. The magnetic device was placed using standard laparoscopic tools and techniques. Eighty-five subjects were followed up for 5 years to evaluate quality of life, reflux control, use of PPIs, and side effects. The GERD-health-related quality of life (GERD-HRQL) questionnaire was administered at baseline to patients on and off PPIs, and after placement of the device; patients served as their own controls. A partial response to PPIs was defined as a GERD-HRQL score of 10 or less on PPIs and a score of 15 or higher off PPIs, or a 6-point or more improvement when scores on vs off PPI were compared.

RESULTS:

Over the follow-up period, no device erosions, migrations, or malfunctions occurred. At baseline, the median GERD-HRQL scores were 27 in patients not taking PPIs and 11 in patients on PPIs; 5 years after device placement this score decreased to 4. All patients used PPIs at baseline; this value decreased to 15.3% at 5 years. Moderate or severe regurgitation occurred in 57% of subjects at baseline, but only 1.2% at 5 years. All patients reported the ability to belch and vomit if needed. Bothersome dysphagia was present in 5% at baseline and in 6% at 5 years. Bothersome gas-bloat was present in 52% at baseline and decreased to 8.3% at 5 years.

CONCLUSIONS:

Augmentation of the lower esophageal sphincter with a magnetic device provides significant and sustained control of reflux, with minimal side effects or complications. No new safety risks emerged over a 5-year follow-up period. These findings validate the long-term safety and efficacy of the magnetic sphincter augmentation device for patients with GERD. ClinicalTrials.gov no NCT00776997.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastroesophageal Reflux / Prosthesis Implantation / Esophageal Sphincter, Lower / Magnets Type of study: Clinical_trials / Observational_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastroesophageal Reflux / Prosthesis Implantation / Esophageal Sphincter, Lower / Magnets Type of study: Clinical_trials / Observational_studies Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2016 Document type: Article